Aktuellt
SENASTE
IRLAB Therapeutics has announced that IRL757, a drug candidate being developed for the treatment of apathy in Parkinson’s disease (PD) and other neurological conditions, is now Phase I-ready. Management is preparing the required documentation to submit a Phase I clinical trial application for regulatory approval, on track with the company’s previously disclosed guided timelines. The company has also reported that it has entered into a grant agreement with the Michael J. Fox Foundation (MJFF) for Parkinson’s Research, and will receive funding amounting to over $2m (c SEK20.2m) to support this programme. IRLAB will use the grant to conduct the Phase I trial for IRL757 in apathy, while also benefiting from the experience and expertise provided by the MJFF.
LÄS MER
